

98. The method of claim 97, wherein a nucleic acid encoding human factor VIII or factor IX is delivered into the cell.

REMARKS


Applicant desires to begin the national stage procedure based on the amended claims 1-49 filed on May 25, 2001. These claims are replaced by, respectively, new claims 50-98. The differences between the amended claims 1-49 and the new claims 50-98 involve converting the "use" claims to the conventional "method of use" format used in this country, and the elimination of multiple dependency. A fair reading of the new claims 50-98 will reveal that the departures from the amended claims 1-49 were for clarification purposes only, and that Applicant did not narrow the claims in any material respect. Therefore, Applicant submits that the new claims 50-98 are entitled to the full range of equivalents.

Early and favorable action is earnestly solicited.

Respectfully submitted,

NORRIS MCLAUGHLIN & MARCUS, P.A.

By


Kurt G. Briscoe
Reg. No. 33,141

220 East 42nd Street - 30th Floor
New York, New York 10017
Phone: (212) 808-0700
Fax: (212) 808-0700